The World Health Organization reports that around 2.2 billion people struggle with vision problems such as near-sightedness ...

Researchers discovered that higher levels of “good” cholesterol (HDL), which is usually considered beneficial for heart ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...

Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Susvimo ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...

Physician–scientists at the University of Utah's John A. Moran Eye Center have published an investigatory review of nine patients who experienced vision complications while taking popular semaglutide ...

The U.S.'s drug regulator has approved Roche's Susvimo drug for the treatment of diabetic macular edema, the leading cause of diabetes-related blindness, the pharmaceutical company said.

More than a million Brits could be living with undiagnosed diabetes, with early detection being key to managing the condition and maintaining a good quality of life ...

The condition appears to be triggered when the optic nerve swells, choking off its blood supply because the nerve's pathway ...